Education
About Us
Working with TipRanks
Follow Us
StemRIM Inc. (JP:4599)
:4599
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥370.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥18.80B
Enterprise Value¥12.42B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.42
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageHaving essentially no debt materially reduces solvency and interest-payment risk, giving management flexibility to prioritize R&D or strategic partnerships. Over 2–6 months this conservatism lowers near-term bankruptcy risk and improves optionality for financing or milestone investments.
Proven Ability To Generate Strong Cash (2023)A strong cash inflow year in 2023 shows the company can convert operations or partnerships into meaningful cash when execution aligns. This demonstrates an underlying operational or commercial pathway that could be reactivated, improving medium-term funding flexibility and strategic execution odds.
Lean Employee BaseA small headcount supports lower fixed operating costs and faster decision cycles, which helps preserve cash and extend runway. For a biotech firm this lean structure enables focused R&D spending and easier scaling of teams only when program milestones justify incremental hires.
Bears Say
Zero Revenue In 2024–2025No reported revenue across two consecutive years means the cost base lacks offsetting commercial income, making margins and profitability impossible in the near term. This structural revenue gap forces reliance on financing and raises execution risk for productization or partnership monetization.
Sustained Recent Cash Burn And VolatilityLarge, persistent outflows and volatile cash generation increase dependency on external funding and heighten dilution risk. This variability undermines planning for multi-stage R&D programs and constrains the company’s ability to fund clinical or commercialization milestones without adverse financing.
Meaningful Equity Decline (dilution Risk)Declining equity reflects accumulated losses and possible dilution, reducing the balance sheet buffer to absorb setbacks. Continued erosion of shareholder capital limits strategic flexibility and raises the risk that future financing will come on dilutive or punitive terms, pressuring long-term returns.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥370.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥18.80B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Jun 17, 2026 which is in 98 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Mar 11, 2026. The company reported -¥6.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.42.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥6.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―